Production Facility Clause Samples

Production Facility. During the Production Term for Phase I, CBSW will provide, in its Facility, a Production Suite, as further described in the third paragraph of Section 3 of Schedule 11.1 attached hereto, which Production Suite will be used exclusively for the manufacture of the Product.

Production Facility. The Swapped Cargo shall be loaded from a Production Facility that complies with Section 3.2 of the DES SPA.

Production Facility. The Swapped Cargo shall be loaded from a Production Facility in respect of which Transporter (on behalf of Project Co) has complied with Section 8.3.4 of the DES SPA for the relevant cargo.

Production Facility. Cytovance is a full-service Contract Development and Manufacturing organization (CDMO) in Oklahoma City, OK employing 220 people. Microbial host services include strain development and process development for cGMP production at the 10 L, 200 L, and 1,000 L scales, with 300 L SUF technology being added in 2018. Mammalian services include cell line development and process development for cGMP production at the 100 L, 250 L, 500 L, and 1,000 L scales with a planned expansion into 2,000 L production for early 2019. With full Analytical Development and Quality Control testing groups, Cytovance provides method transfer, development, qualification, and validation, and in-process, release, and stability testing. Cytovance also has clinical-grade, liquid vial fill/finish capabilities, Master, Working, and End-of-Production cell banking, viral validation, and Process Characterization and Validation services. Cytovance operates out of four (4) facilities - three (3) located within the Oklahoma University Research Park, close to the city’s central business district encompassing over 100,000 square feet of laboratories, cGMP Drug Product and mammalian manufacturing, and administration space. Just north of the main campus is a 30,000 ft2 microbial cGMP manufacturing building, and a 100,000 ft2 cGMP warehouse. Cytovance welcomes appropriate Synthorx representatives to tour the facilities and perform a detailed review of Cytovance’s facility design, equipment, validation, process flow, and quality systems. pH ▇▇▇▇▇▇▇ 350 pH meter ▇▇▇▇▇▇▇ Toledo Conductivity Mettler Mettler Osmolality Advanced Instruments Micro-Osmometer 3300 N/A % Purity/Aggregates Waters 2695 HPLC Agilent 1100/1200 HPLC/Waters 2695 HPLC/Acquity H-Class Bio UPLC Bioburden Millipore Milliflex single head pump system Certified biological safety cabinet Precision Incubator N/A Endotoxin Molecular Devices Spectra Max 384 plus UV/Vis plate reader/ Endosafe PTS Molecular Devices Spectra Max M2e/ Endosafe PTS Protein content ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ DU 730 spectrophotometer Molecular Devices Spectra Max 384 Plus Molecular Devices Spectra Max M2e ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ DU 730 spectrophotometer Eppendorf Biophotometer Molecular Devices Spectra Max M2e ELISA Lab Line Instruments Titer Plate Shaker ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ MW96/384 plate washer Molecular Devices Spectra Max 384 plus Molecular Devices Spectra Max M2e BioTek Synergy / neo2 Multimode Reader Lab Line Instruments and VWR Titer Plate Shakers ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ MW96/384 plate washer ...

Production Facility the facilities for the receipt, production, storage, and loading of LNG onto LNG vessels and the berthing of LNG vessels, including any Gas pretreatment and processing facilities, liquefaction facilities, storage tanks, utilities, terminal facilities, and associated port and marine facilities, and all other related facilities both inside and outside the LNG plant, inclusive of all LNG production trains, including any future expansions or modifications thereto. If a cargo delivered to DES Buyer hereunder was loaded onto the LNG Tanker from the storage tanks at an LNG receiving facility performing reload services, then the Production Facility for such cargo is the LNG receiving and reloading facility at which the LNG Tanker used to deliver such cargo to DES Buyer loads such cargo; Provisional Invoices: as defined in Clause 12.1.4(A);

Production Facility. The responsibility of the supplier will be to ensure the availability of production machine hardware and consumables during the entire period of operation. The Purchaser shall confirm the commencement and duration of the project to convert all old drivers licence issued to the new proposed Drivers Licence Card.

Production Facility. Swapped Cargo Force Majeure relief in respect of Transporter for an event affecting a Production Facility or Connecting Pipeline: (A) shall only be available with respect to cargoes: (i) that are scheduled to be loaded at such Production Facility in the applicable DES Ninety Day Schedule or DES ADP for such Contract Year, or (to the extent that the DES ADP for the following Contract Year has been issued by the Transporter) in the DES ADP for the following Contract Year and (ii) in respect of a Nominal LNG Facility, that would be scheduled for delivery in a future Contract Year(s) for which the DES ADP has not yet been issued by Transporter, provided that such Swapped Cargo Force Majeure relief shall, in respect of any individual Nominal LNG Facility, be limited to a percentage of the annual contract quantity for the relevant Contract Year equal to the percentage identified for such Nominal LNG Facility in the relevant notice provided by Transporter at the time such Nominal LNG Facility is nominated pursuant to Section 3.2.4(b) of the DES SPA; and (B) shall not be available for an event affecting such Production Facility (or Connecting Pipeline in respect thereof) if such Production Facility (or Connecting Pipeline) was affected by, or could reasonably have been expected to be affected by, such Swapped Cargo Force Majeure event at the time such Production Facility was nominated pursuant to the DES SPA for the relevant cargo.

Production Facility. During the Contract Period, the Collaboration Program shall be performed in the Production Facility. The System and Improvements shall be assembled, constructed and maintained in the Production Facility as more fully described and provided below. ArQule covenants that the Production Facility shall be made suitable in all respects for the performance of its duties pursuant to this Agreement and shall be maintained in such condition during the term of this Agreement. 2.5.1 ArQule shall be responsible for the following operations in the Production Facility: [*]. 2.5.2 Pfizer may inspect environmental health and safety procedures in the Production Facility and may make recommendations with respect to improvements to ensure compliance with local, state and federal regulations. At ArQules' own expense, ArQule will make all such improvements to the Production Facility as may be required to comply with any government regulations as identified by Pfizer or the responsible government agency. If Pfizer seeks to improve the standards of environmental health and safety beyond those required by law, Pfizer may do so at Pfizer's own expense. 2.5.3 Pfizer may inspect security procedures in the Production Facility and may seek to improve such procedures at Pfizer's own expense. ------------------ *Confidential treatment has been requested for the marked portion. 2.5.4 ArQule Staff, Pfizer Staff and Supplementary Staff will co-occupy the Production Facility. (i) The skills of ArQule Staff with respect to disciplines, roles. level of education and ArQule employment experience will be as described in the Collaboration Plan. (ii) [*] will be responsible for management of ArQule Staff and [*] or his appointee will be responsible for management of Pfizer Staff and Supplementary Staff. The day to day operations of the Production Facility shall be the responsibility of [*] or his successor pursuant to Section 2.10. (iii) Subject to the terms and conditions of Section 2.5.4 (iv), commencing on [*], with [*] months written notice, Pfizer may substitute ArQule Staff with Pfizer Staff for the performance of Plans; provided, however, at least [*] ArQule Staff remain in the facility. Pfizer will replace ArQule Staff with an equivalent number of Pfizer Staff, so that the total number of FTEs dedicated to Pfizer Compound production is [*]. Commencing [*], until the termination of this Agreement. Pfizer Staff may be increased to a maximum of [*] FTEs so that there may be as many as [*] FTE...

Production Facility a. agrees to dedicate at least fifteen (15) and up to twenty five (25) high temperature furnace systems for LSO crystal growth by * technique for CTI within the next 24 months starting July 1999. Such furnaces must be sufficient for the growth of LSO crystals which meet the single crystal specifications set forth in Exhibit A attached hereto. b. CTI agrees by initiating this contract commitment and by agreeing to enter into an annual purchase contract for LSO to assist * in financing construction of these new furnaces including power back-up systems and the necessary Iridium crucibles, rods and lids located at the * facility for growth of LSO crystals. c. The * crystal production facility will include trained staff of engineers and technicians as necessary to keep all the furnaces in continuous operation and to produce LSO crystals meeting the specifications in Exhibit A. d. may use the furnaces described above dedicated to CTI for * purposes when they are not being utilized for CTI purposes. * agrees to immediately return the furnace systems to the dedicated use of CTI upon the request of CTI. *Omitted information is the subject of a request for confidential treatment pursuant to Rule 406 under the Securities Act of 1933 and has been filed separately with the Securities and Exchange Commission.